home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  Asthma: New Drug Targets & Innovative Therapeutics  
  January 17, 2001

Biochemistry / Immunology

 
     
  SMi, London
28th - 29th March, 2001


Keep abreast of the exciting innovations within asthma research today by attending…..
ASTHMA: NEW DRUG TARGETS & INNOVATIVE THERAPEUTICS
28th & 29th March 2001, The Hatton, London

A unique opportunity to learn from leading industry experts including:
 Dr Joan Soranio, Principal Epidemiologist, Worldwide Epidemiology, GlaxoWellcome
 Dr Dereck Tait, Clinical Programme Head, GlaxoWellcome
 Douglas Hay, Group Director, SmithKline Beecham
 Dr Paul Wright, Associate Director, Product Development, AstraZeneca
 Gary Peltz, Head, Genetics & Genomics, Roche Bioscience
 Dr Kenneth Holroyd, Senior Vice President, Clinical Research & Regulatory Affairs, Magainin
 Prof Heinz Werner Radtke, Executive Vice President, Research & Development,
Byk Gulden
 Dr Beatrix Fyrnys, Pharmaceutical Development & Head of Analytics, Asta Medica
 Dr James Mannion, President & Chief Operating Officer, Epigenesis
 Dr Joel Kline, Associate Professor, Coley Pharmaceutical Group
 Dr Mark Parry Billings, Director, Research & Development, Innovata
 Dr Robert Humphreys, President & Chief Scientific Officer, Antigen Express
 Dr Michael Placke, Vice President, Business Development, Battelle Pulmonary Therapeutics
 Dr Kulasiri Gunawardena, Director, Clinical Research, Chiltern International
 Dr Rodney Hornbake, Senior Vice President & Chief Medical Officer, Gentiva Health Services
 Anne Delaney, Head, Immune Disorders & Inflammation, Datamonitor
 Dr Nick Lench, Programme Manager, Inflammation Biology, Oxagen
 Prof Albrecht Bufe, Department Leader, Experimental Pneumology & Clinical Research Group – ‘Viral Infection and Chronic Pulmonary Disease’, Ruhr-University Bochum

Chaired by:
 Prof Fan Chung, Professor of Respiratory Medicine, Imperial College School of Medicine
 Prof Paul Nicholls, Professor of Pharmacology, Cardiff University









Day One – 28th March

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Prof Paul Nicholls, Professor of Pharmacology, Cardiff University

THE NATURAL HISTORY OF ASTHMA
9.10 The relevance of the natural history of a disease to drug development
 The problem of asthma
 Defining asthma
 Relationship of atopy, airway hyper-responsiveness (AHR) and airway inflammation to
clinical asthma
 Natural history of atopy, AHR, airway inflammation
 Influence of airway remodelling on airflow obstruction and airway hyper-responsiveness
 Relevance of these to the design of clinical trials in asthma
Dr Kulasiri Gunawardena, Director, Clinical Research, Chiltern International

STRATEGIC OVERVIEW OF THE ASTHMA MARKET 2001-2007
9.40 A Datamonitor analysis
 The global asthma market
 Patient education and compliance
 Pipeline analysis
 Meeting the unmet needs of asthma
 Environmental factors influencing the future asthma market
 Market forecasts to 2007
 Strategies for success in a competitive environment
Anne Delaney, Head, Immune Disorders & Inflammation, Datamonitor

FROM GENES TO ASTHMA THERAPEUTICS
10.20 The challenges in turning a molecular target into a marketable drug
 Identification of targets: too many targets too little time?
 Target identification versus target validation
 Value and limitations of animals. Don’t forget the patient!
 Is quicker better?
 From target to patentable ligand-reverse pharmacology
 Diagnostics and molecular medicine - the way forward?
Douglas Hay, Group Director, SmithKline Beecham

11.00 Morning Coffee

CPG DNA AND ASTHMA
11.20 Promise for prevention and treatment of asthma
 CpG oligodeoxynucleotides are effective in preventing manifestations of asthma in a murine model, including IgE induction, airway eosinophilia, and bronchial hyperreactivity
 As immunotherapy, CpG DNA can downregulate inflammatory responses in established asthma
 CpG DNA is effective when administered through a variety of routes, including parenteral, transmucosal, and oral
 Preliminary human studies are underway in humans
Dr Joel Kline, Associate Professor, Coley Pharmaceutical Group

THE ROLE OF INTERFERON-ALPHA IN ASTHMA
12.00 State of the art asthma therapy with IFN-alpha
 IFN-alpha as a linker molecule between viral infection and atopic asthma
 Molecular regulation of IFN-alpha in viral infection and atopic immune response
 IFN-alpha as a diagnostic tool for asthma? First study results
 Phase 1 and 2 studies for combined treatment with IFN-alpha and allergen immunotherapy in asthma
Prof Albrecht Bufe, Department Leader, Experimental Pneumology & Clinical Research Group – ‘Viral Infection and Chronic Pulmonary Disease’, Ruhr-University Bochum

12.40 Networking Lunch

TARGETING IL-9 DURING THE INFLAMMATORY RESPONSE
2.20 The Magainin and Genentech collaboration
 Employment of functional genomics to discover therapeutic targets for asthma and allergy
 The role of IL-9 in asthma
 Preclinical research programme: IL-9 acts directly and specifically to promote lung inflammation in asthma
 Development and commercialisation of an IL-9 antibody for human asthma treatments
Dr Kenneth Holroyd, Senior Vice President, Clinical Research & Regulatory
Affairs, Magainin

SELECTING AN EFFECTIVE DELIVERY TECHNOLOGY
3.00 An integral component of a successful asthma product
 Overview of delivery options and recent advances
 Selection of the optimal technology
 Key challenges in development and registration
 Future perspectives
Dr Mark Parry Billings, Director, Research & Development, Innovata

3.40 Afternoon Tea

RELENZA - INHALED ANTIVIRAL THERAPY FOR INFLUENZA
4.00 Current data on the Relenza development programme: efficacy and safety data in asthmatics
 What is Relenza?
 Mechanism of action: targeted delivery
 Preclinical studies
 Clinical data to date
 Clinical impact of influenza in asthmatic patients
 Socioeconomic impact of influenza - global burden of illness and impact on patients with asthma
 Predicting the impact of Relenza on future asthma management
Dr Dereck Tait, Clinical Programme Head, GlaxoWellcome

THE FUTURE FOR INHALATION DEVICES
4.30 How do MDIs, DPIs, nebulisers and others compare?
 Complexity vs simplicity
 Device vs formulation
 Systemic vs topical
 Environmental factors
Dr Paul Wright, Associate Director, Product Development, AstraZeneca

5.00 Chairman’s Closing Remarks and Close of Day One

5.10 Networking Drinks Reception

Day Two – 29th March

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks
Prof Fan Chung, Professor of Respiratory Medicine, Imperial College School
of Medicine

PHARMACOGENETICS AND PHARMACOEPIDEMIOLOGY OF ASTHMA
9.10 The impact of genetics and genomics in the general population
 Drivers of pharmacogenetics, pharmacogenomics and pharmacoepidemiology
 Asthma pharmacogenetic initiatives and new targets
 Asthma trials to date
 From the gene to the population
 Human genetics and the future of healthcare
Dr Joan Soranio, Principal Epidemiologist, Worldwide Epidemiology, GlaxoWellcome

GENETIC AND GENOMIC APPROACHES TO UNDERSTANDING ASTHMA
9.40 Case study: complement in asthma
 Novel analytic methods for murine experimental genetic model of asthma
 Accelerated identification of genetic loci using genetic and genomic technologies
 Genetic regulation of innate and adaptive immune system interface
Gary Peltz, Head, Genetics & Genomics, Roche Bioscience

COMMERCIALISING NOVEL AND COMPLEX ASTHMA THERAPIES
10.20 How to turn an effective therapy into the standard of care
 Navigating health plan and US governmental payment policies
 Preparing payers for the launch of new therapies
 Informing and energising patient communities
 Building clinical support services for physicians and patients
 Assisting physicians in developing clinical programs
 Emerging American health policies that will impact marketing and distribution strategies
Dr Rodney Hornbake, Senior Vice President & Chief Medical Officer, Gentiva Health Services

11.00 Morning Coffee

DEVELOPMENT OF MASTER ALLERGIC MEDIATORS
11.20 Case study: Roflumilast
 The aim: development of non-steroidal anti-inflammatory treatment in asthma and chronic bronchitis
 PDE inhibitors: molecular mechanism of action
 Clinical data to date
 Predicted impact on asthma therapeutics
Prof Heinz Werner Radtke, Executive Vice President, Research & Development,
Byk Gulden

IDENTIFICATION OF NOVEL ASTHMA GENES
12.00 SNPing AWAY at asthma susceptibility loci
 Complex disease mapping
 Linkage disequilibrium islands
 SNPs vs haplotypes
 Validation of novel genes
Dr Nick Lench, Programme Manager, Inflammation Biology, Oxagen

12.40 Networking Lunch

USING ADVANCED PULMONARY DELIVERY TECHNOLOGY TO IMPROVE CLINICAL OUTCOMES IN ASTHMA PATIENTS
2.00 Case studies: Battelle Pumonary Therapeutics
 Factors affecting deposited dose patterns
 Understanding patient use and misuse of inhalation devices
 Improved fev1 responses while using lower overall doses of b-agonists
 Approaches to controlling unwanted side effects
Dr Michael Placke, Vice President, Business Development, Battelle Pulmonary Therapeutics

ANTISENSE OLIGONUCLEOTIDES ATTENUATE DISEASE-RELATED PROTEINS
2.40 Respirable Antisense Oligonucleotides (RASONs): the revolutionary therapy pioneered by Epigenesis
 Target validation technology
 Respirable antisense oligonucleotide platform technology
 Primate models of respiratory disease
 Pharmacogenomics technology
 Drugs in development: EPI-2010 (Durason™)
Dr James Mannion, President & Chief Operating Officer, Epigenesis

3.20 Afternoon Tea

THE ASTA MEDICA MULTI-DOSE DRY POWDER INHALER (DPJ)
3.40 A novel inhaler device
 Development objectives
 Design and function
 Robustness and reliability
 Performance and efficacy characteristics
Dr Beatrix Fyrnys, Pharmaceutical Development & Head of Analytics, Asta Medica

ANTIGEN-SPECIFIC IMMUNOSUPPRESSION WITH Ii-KEY HYBRIDS
4.20 Case study: Antigen Express
 Antigenic peptides: spilled from MHC Class II by Ii-Key compounds
 Hybrids of Ii-Key-spacer-antigenic epitope charge potently
 Th2 or Th1 responses depending on method
Dr Robert Humphreys, President & Chief Scientific Officer, Antigen Express

5.00 Chairman's Closing Remarks and Close of Conference
ASTHMA: NEW DRUG TARGETS & INNOVATIVE THERAPEUTICS


Dear Pharmaceutical Executive,

The world-wide prevalence of asthma is now reaching epidemic proportions afflicting over 50 million individuals globally and continues to escalate at an alarming rate. In addition, asthma is a major cost to healthcare systems comprising over 1% of the total healthcare bill in the USA – the highest for any single disease.

For these reasons drug developers and physicians have been prompted to review current treatments and improve therapeutic approaches to asthma management. Traditionally asthma medicines have helped the symptoms, but have done nothing for the underlying inflammation associated with the disease. It has now been recognised that the symptoms of asthma would be better treated with molecules that actually block particular steps within the cellular inflammatory cascade in conjunction with improved drug delivery systems.

With this knowledge in mind, our challenge at SMi was to assemble key industry peers within asthma research that would provide pertinent and up-to-date information on the key innovations within this exciting field. As you can see from this brochure we have more than achieved our goal.

Why should you attend this event?
This is your unique opportunity to meet senior industry executives and seek their advice and opinions. This essential conference will feature the development and latest advancements of revolutionary therapeutic agents designed for the treatment of asthma. Covering market trends, new combination therapies, therapeutic anti-bodies, targeting of specific cytokines, pharmacogenetics, pharmacoepidemiology and delivery problems – this event is imperative for all pharmaceutical executives and researchers working in this fast-moving area of drug development.

To attend this essential forum please register now using the booking form on the back of the brochure or visit www.smi-online.co.uk/asthma.asp to register online.

I look forward to seeing you in London in March.

Yours faithfully,
Susie Palmer Ph.D.
Conference Producer
Tel: +44 (0)20 7827 6042
Email: spalmer@smi-online.co.uk


 
 
Organized by: SMi
Invited Speakers: Confirmed speakers:

 Dr Joan Soranio, Principal Epidemiologist, Worldwide Epidemiology, GlaxoWellcome
 Dr Dereck Tait, Clinical Programme Head, GlaxoWellcome
 Douglas Hay, Group Director, SmithKline Beecham
 Dr Paul Wright, Associate Director, Product Development, AstraZeneca
 Gary Peltz, Head, Genetics & Genomics, Roche Bioscience
 Dr Kenneth Holroyd, Senior Vice President, Clinical Research & Regulatory Affairs, Magainin
 Prof Heinz Werner Radtke, Executive Vice President, Research & Development,
Byk Gulden
 Dr Beatrix Fyrnys, Pharmaceutical Development & Head of Analytics, Asta Medica
 Dr James Mannion, President & Chief Operating Officer, Epigenesis
 Dr Joel Kline, Associate Professor, Coley Pharmaceutical Group
 Dr Mark Parry Billings, Director, Research & Development, Innovata
 Dr Robert Humphreys, President & Chief Scientific Officer, Antigen Express
 Dr Michael Placke, Vice President, Business Development, Battelle Pulmonary Therapeutics
 Dr Kulasiri Gunawardena, Director, Clinical Research, Chiltern International
 Dr Rodney Hornbake, Senior Vice President & Chief Medical Officer, Gentiva Health Services
 Anne Delaney, Head, Immune Disorders & Inflammation, Datamonitor
 Dr Nick Lench, Programme Manager, Inflammation Biology, Oxagen
 Prof Albrecht Bufe, Department Leader, Experimental Pneumology & Clinical Research Group – ‘Viral Infection and Chronic Pulmonary Disease’, Ruhr-University Bochum

Chaired by:
 Prof Fan Chung, Professor of Respiratory Medicine, Imperial College School of Medicine
 Prof Paul Nicholls, Professor of Pharmacology, Cardiff University
 
Deadline for Abstracts: all slots now taken
 
Registration: by internet - www.smi-online.co.uk/asthma.asp
E-mail: spalmer@smi-online.co.uk
 
  Posted by:   Dr Susie Palmer  
Host: 213.38.112.46
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.